AUSTIN, Texas--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a biopharmaceutical company developing the G-Pen™, a glucagon rescue pen for emergency treatment of severe hypoglycemia, has completed a Series A preferred stock financing for approximately $1.5 million. The financing was led by the Central Texas Angel Network (CTAN), with significant participation of life science investors including family offices from California and Tennessee.
